Paper41304752
Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions.
Pérez-Ortega HU and 8 others. Pharmaceutics, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions. Papers, record 41304752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41304752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Camptothecin in Cancer Therapy: Current Challenges and Emerging Strategies with Nanoemulsions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References185
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30509782 | Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents. | Bioorg Med Chem Lett | 2019 | https://conductscience.org/library/papers/30509782 | PubMed |
| 2 | 29844300 | Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines. | Pharmaceuticals (Basel) | 2018 | https://conductscience.org/library/papers/29844300 | PubMed |
| 3 | 38534365 | TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling. | Cells | 2024 | https://conductscience.org/library/papers/38534365 | PubMed |
| 4 | 26679767 | Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents. | Med Princ Pract | 2016 | https://conductscience.org/library/papers/26679767 | PubMed |
| 5 | 30858085 | Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. | Nanomedicine | 2019 | https://conductscience.org/library/papers/30858085 | PubMed |
| 6 | 40805204 | Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40805204 | PubMed |
| 7 | 37543063 | Lipid based formulations as supersaturating oral delivery systems: From current to future industrial applications. | Eur J Pharm Sci | 2023 | https://conductscience.org/library/papers/37543063 | PubMed |
| 8 | 33163147 | Functional roles in cell signaling of adaptor protein TRADD from a structural perspective. | Comput Struct Biotechnol J | 2020 | https://conductscience.org/library/papers/33163147 | PubMed |
| 9 | 23836376 | Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines. | Oncol Rep | 2013 | https://conductscience.org/library/papers/23836376 | PubMed |
| 10 | 36705281 | Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis. | J Manag Care Spec Pharm | 2023 | https://conductscience.org/library/papers/36705281 | PubMed |
| 11 | 31415916 | Irinotecan: 25 years of cancer treatment. | Pharmacol Res | 2019 | https://conductscience.org/library/papers/31415916 | PubMed |
| 12 | 39061709 | Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/39061709 | PubMed |
| 13 | 29520731 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. | Clin Pharmacokinet | 2018 | https://conductscience.org/library/papers/29520731 | PubMed |
| 14 | 23006513 | Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/23006513 | PubMed |
| 15 | 39404324 | Enhancing the Efficacy of Active Pharmaceutical Ingredients in Medicinal Plants through Nanoformulations: A Promising Field. | Nanomaterials (Basel) | 2024 | https://conductscience.org/library/papers/39404324 | PubMed |
| 16 | 33324678 | Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. | Front Mol Biosci | 2020 | https://conductscience.org/library/papers/33324678 | PubMed |
| 17 | 39201338 | Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39201338 | PubMed |
| 18 | 37586663 | A critical review of the novelties in the development of intravenous nanoemulsions. | Eur J Pharm Biopharm | 2023 | https://conductscience.org/library/papers/37586663 | PubMed |
| 19 | 27671528 | Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27671528 | PubMed |
| 20 | 32531842 | Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. | J Leukoc Biol | 2021 | https://conductscience.org/library/papers/32531842 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42924725 | Epigenetic Landscape and Regulation of Secondary Metabolite Accumulation Implicated in Anticancer and Nutraceuticals. | Epigenomes | 2026 | https://conductscience.org/library/papers/42924725 | PubMed |
| 42514944 | Novel Camptothecin-Based Lipid Conjugated with Steroids and Triterpene Acids: Enhanced Cellular Uptake and Topoismerase I Inhibition. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42514944 | PubMed |
| 41888388 | Topoisomerase I/II inhibitors: from established drugs to next-generation therapeutics. | Inflammopharmacology | 2026 | https://conductscience.org/library/papers/41888388 | PubMed |
| 41872836 | Multifunctional chitosan-doxorubicin nanocarriers: advancing targeted breast cancer chemotherapy. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41872836 | PubMed |
| 41754919 | Advances in Polymer Micelles for Cancer Therapy: From Conventional to Smart Delivery Systems. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41754919 | PubMed |
| 41752469 | Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions. | Molecules | 2026 | https://conductscience.org/library/papers/41752469 | PubMed |
| 41683797 | Mining the Hidden Pharmacopeia: Fungal Endophytes, Natural Products, and the Rise of AI-Driven Drug Discovery. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41683797 | PubMed |
| 41599661 | Innovations in the Delivery of Bioactive Compounds for Cancer Prevention and Therapy: Advances, Challenges, and Future Perspectives. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41599661 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41304752
GET https://conductscience.org/api/papers/v1/41304752/references?page=2